This study will collect data on standard of care chemotherapy with or without a new investigational medication in dogs with osteosarcoma (OSA). All dogs will undergo limb amputation here at Penn Vet followed by standard of care chemotherapy. Half of study dogs will go on to receive an oral medication, Rapamycin, after the chemotherapy is complete. Rapamycin has been used as an anti-rejection drug in humans following organ transplant; recent studies suggest that it may have anti-cancer properties through inhibition of a specific pathway critical to cancer progression.
- Dogs with newly diagnosed OSA who have received no prior treatment for cancer
- Dogs weighing at least 25kg (55lbs)
- Dogs with OSA of the leg which is amenable to limb amputation
- Dogs with no evidence of metastasis at the time of enrollment
- Costs of standard of care chemotherapy and, if applicable, Rapamycin are covered by the study
- A stipend in the amount of $1000 is available to partially cover the cost of limb amputation
Please contact the VCIC at 215-573-0302 or by email at firstname.lastname@example.org if you would like more information about this study.